PortfoliosLab logoPortfoliosLab logo
National Research Corporation (NRC)
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN
US6373722023
CUSIP
637372202
IPO Date
Oct 10, 1997

Highlights

Market Cap
$370.28M
Enterprise Value
$449.19M
EPS (TTM)
$0.52
PE Ratio
32.72
Total Revenue (TTM)
$137.39M
Gross Profit (TTM)
$77.40M
EBITDA (TTM)
$30.23M
Year Range
$9.76 - $22.79
ROA (TTM)
8.60%
ROE (TTM)
82.91%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


National Research Corporation

Often compared with NRC:
NRC vs. COSTNRC vs. FORRNRC vs. GDE

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in National Research Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

National Research Corporation (NRC) has returned -8.70% so far this year and 37.22% over the past 12 months. Over the last ten years, NRC has returned 2.77% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.


National Research Corporation

1D
-0.93%
1M
27.79%
YTD
-8.70%
6M
35.24%
1Y
37.22%
3Y*
-24.62%
5Y*
-16.64%
10Y*
2.77%

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since May 23, 2013, NRC's average daily return is +0.04%, while the average monthly return is +0.69%. At this rate, your investment would double in approximately 8.4 years.

Historically, 51% of months were positive and 49% were negative. The best month was May 2019 with a return of +28.8%, while the worst month was Feb 2026 at -34.1%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 5 months.

On a daily basis, NRC closed higher 51% of trading days. The best single day was Mar 19, 2020 with a return of +19.3%, while the worst single day was Mar 16, 2020 at -20.7%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20268.36%-34.07%27.79%-8.70%
2025-5.50%-12.48%-11.51%-11.25%18.93%25.28%-25.60%17.52%-12.24%4.54%27.17%11.42%10.00%
2024-0.40%2.34%-1.46%-13.53%-18.01%-17.84%11.07%-10.55%0.81%-20.69%8.44%-9.67%-54.49%
202324.45%-2.71%-3.39%0.05%3.15%-2.83%-1.38%-2.59%8.79%-4.76%-1.96%-4.22%9.63%
20220.19%-4.37%0.28%-13.49%4.64%7.31%-0.99%-10.00%17.37%2.34%-4.89%-3.40%-8.23%
20215.96%14.06%-9.37%9.82%-6.76%-3.79%14.99%2.31%-21.69%2.68%-7.51%3.96%-1.83%

Benchmark Metrics

National Research Corporation has an annualized alpha of -2.27%, beta of 0.92, and R² of 0.15 versus S&P 500 Index. Calculated based on daily prices since May 24, 2013.

  • This stock participated in 124.37% of S&P 500 Index downside but only 75.67% of its upside — more exposed to losses than it benefited from rallies.
  • R² of 0.15 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
-2.27%
Beta
0.92
0.15
Upside Capture
75.67%
Downside Capture
124.37%

Return for Risk

Risk / Return Rank

NRC ranks 60 for risk / return — better than 60% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.


NRC Risk / Return Rank: 6060
Overall Rank
NRC Sharpe Ratio Rank: 6464
Sharpe Ratio Rank
NRC Sortino Ratio Rank: 6060
Sortino Ratio Rank
NRC Omega Ratio Rank: 5959
Omega Ratio Rank
NRC Calmar Ratio Rank: 5959
Calmar Ratio Rank
NRC Martin Ratio Rank: 6060
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for National Research Corporation (NRC) and compare them to a chosen benchmark (S&P 500 Index).


NRCBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

0.65

0.90

-0.24

Sortino ratio

Return per unit of downside risk

1.20

1.39

-0.18

Omega ratio

Gain probability vs. loss probability

1.16

1.21

-0.05

Calmar ratio

Return relative to maximum drawdown

0.78

1.40

-0.62

Martin ratio

Return relative to average drawdown

1.97

6.61

-4.64

Explore NRC risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History

National Research Corporation provided a 3.30% dividend yield over the last twelve months, with an annual payout of $0.56 per share.


0.00%1.00%2.00%3.00%4.00%$0.00$0.50$1.00$1.5020152016201720182019202020212022202320242025
Dividends
Dividend Yield
PeriodTTM20252024202320222021202020192018201720162015
Dividend$0.56$0.52$0.48$1.48$0.84$0.48$0.21$0.78$0.63$0.40$0.34$0.62

Dividend yield

3.30%2.77%2.72%3.74%2.25%1.16%0.49%1.18%1.65%1.07%1.79%3.87%

Monthly Dividends

The table displays the monthly dividend distributions for National Research Corporation. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026$0.00$0.00$0.16$0.16
2025$0.00$0.00$0.12$0.00$0.00$0.12$0.00$0.00$0.12$0.00$0.00$0.16$0.52
2024$0.00$0.00$0.12$0.00$0.00$0.12$0.00$0.00$0.12$0.00$0.00$0.12$0.48
2023$0.00$0.00$0.12$0.00$0.00$0.12$0.00$0.00$1.12$0.00$0.00$0.12$1.48
2022$0.00$0.00$0.24$0.00$0.00$0.24$0.00$0.00$0.24$0.00$0.00$0.12$0.84
2021$0.00$0.00$0.00$0.12$0.00$0.12$0.00$0.00$0.12$0.00$0.00$0.12$0.48

Dividend Yield & Payout


Dividend Yield

National Research Corporation has a dividend yield of 3.30%, which is quite average when compared to the overall market.

Payout Ratio

National Research Corporation has a payout ratio of 94.65%, which is above the market average. This might signify the company's strong earnings or financial health. However, it could also hint at a more mature business phase with potentially slower growth.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the National Research Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the National Research Corporation was 84.10%, occurring on Apr 21, 2025. The portfolio has not yet recovered.

The current National Research Corporation drawdown is 72.43%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-84.1%Jan 29, 20201314Apr 21, 2025
-41.14%May 29, 2013592Oct 1, 2015315Dec 30, 2016907
-26.4%Jan 26, 201823Feb 28, 201878Jun 20, 2018101
-18.55%Oct 4, 201731Nov 15, 201747Jan 25, 201878
-17.01%Aug 1, 201954Oct 16, 201948Dec 24, 2019102

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of National Research Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how National Research Corporation is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for NRC, comparing it with other companies in the Diagnostics & Research industry. Currently, NRC has a P/E ratio of 32.7. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for NRC relative to other companies in the Diagnostics & Research industry. Currently, NRC has a P/S ratio of 2.8. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for NRC in comparison with other companies in the Diagnostics & Research industry. Currently, NRC has a P/B value of 26.5. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items